Biomea Fusion (BMEA) Receivables - Other (2020 - 2021)
Biomea Fusion (BMEA) posted Receivables - Other of $115000.0 for Q3 2021, down 42.5% sequentially from $200000.0 in Q2 2021.
Biomea Fusion (BMEA) Receivables - Other (2020 - 2021) Analysis & Trends
Biomea Fusion has reported Receivables - Other for 2 years, with the latest figure at $115000.0 in Q3 2021.
- Quarterly Receivables - Other changed N/A year-over-year to $115000.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $115000.0 (changed N/A YoY) and the FY2020 annual result came in at $8000.0, changed N/A from the prior year.
- Receivables - Other slipped to $115000.0 in Q3 2021 per BMEA's latest filing, from $200000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $200000.0 in Q2 2021 and troughed at $8000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 115,000.00 |
| Sep 30, 2021 | 115,000.00 |
| Jun 30, 2021 | 200,000.00 |
| Jun 30, 2021 | 200,000.00 |
| Dec 31, 2020 | 8,000.00 |
| Dec 31, 2020 | 8,000.00 |